ABSTRACT
A change of therapy should be considered for patients if they experience sustained rebound in viral load levels, having either had previously undetectable levels or never achieved undetectable levels on their current treatment regimen after 24–36 weeks. The likelihood of achieving an undetectable viral load on changing therapy is predicted by the number of active drugs in the new regimen, plus factors influencing tolerability and adherence. The decision to change therapy should be guided by the availability of a treatment option that is likely to have the potency to suppress viral load to undetectable levels (<50 copies/ mL) and which the patient is likely to be able to adhere to and tolerate.
Articolo presente in – HAART and correlated pathologies n. 9 –
Download del’articolo 
